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Introduction
Colorectal cancer is the third most common cancer worldwide with more than one million patients diagnosed each year, of which 50% will develop metastatic disease (1 , 2) . Recent efforts to improve the treatment of advanced colorectal cancer (mCRC) has led to the development of monoclonal antibodies such as cetuximab or its fully-humanized version, panitumumab, that inhibit the activation of the Epidermal Growth Factor Receptor (EGFR) and its downstream pathways (namely RAS-RAF-MAPK and PI3K-PTEN-AKT) that promote cell growth, proliferation and inhibition of apoptosis. Evidence shows, however, that patients with KRAS-mutant tumors receive little or no benefit from anti-EGFR therapies as single agents or combined with chemotherapy (3) (4) (5) (6) . These findings led the European Medicine Agency and the Food and Drug Administration to restrict the use of cetuximab and panitumumab to patients with wild-type KRAS tumors and, more recently, to NRAS wild-type tumors.
From studies including patients with apparently wild-type KRAS tumors, the response rates to cetuximab or panitumumab therapy ranged from only 40 to 60% (7) which results in a large fraction of patients without any known causes for treatment failure. The presence of alterations in other genes in the EGFR-dependent signaling pathways (8) (9) (10) is responsible for some of the nonresponding cases. However, these alterations do not account for all examples of primary or secondary resistance to anti-EGFR therapy. Recent works have demonstrated that secondary resistance to such therapies is associated with the emergence or selection of KRAS-mutated subclones in KRAS wild-type patients at the time of diagnosis (11) . The presence of a low fraction of KRAS-mutated cells within tumors, which is not detectable by commonly used procedures, could explain secondary resistances. Two hypotheses have been proposed. First, intra-tumor heterogeneity of KRAS mutations results in detection failures when analyzing a single biopsy (12) . Additionally, the limited sensitivity of conventional methods used for the detection of KRAS mutations leads to false negative results (1, 5) . Therefore, the performance of molecular analysis technologies to detect KRAS mutant sub-clones at the time of diagnosis, and the consequence of sub-clone mutations for treatment of mCRC patients are critically important. A highly sensitive and specific method of detection is necessary to probe the heterogeneity and the low prevalence of mutated DNA from the tumor. Furthermore, a quantitative detection technology allows analyzing response rate or progression free survival according to the absolute quantity of KRAS mutant allele, which enables definition of a clinically-relevant threshold.
Sanger sequencing offers a sensitivity of ca. 20% to detect KRAS mutant alleles (13). This poor sensitivity has led to the use of alternative methods, such as pyrosequencing (14) (15) (16) or quantitative PCR (qPCR) (3, 17) , which have sensitivities ranging from 1% to 10% for the detection Author Manuscript Published OnlineFirst on September 23, 2014; DOI: 10.1158/1078-0432.CCR- of mutant DNA in a background of wild-type DNA (18). Picodroplet-digital PCR (dPCR) has recently emerged as a highly sensitive and quantitative approach for rare sequence detection (19).
Droplet-based digital PCR technology is based on parallel amplification of up to millions of individual DNA fragments within identical compartments (i.e., droplets) and sensitivity is limited only by the number of molecules that can be amplified and detected (i.e., the number of PCRpositive compartments) and the false positive rate of the mutation detection assay. Previous reports demonstrate detection of one mutant KRAS gene in 200,000 wild-type KRAS genes in genomic DNA (20) . A number of other examples of picodroplet-dPCR for highly sensitive mutation detection has recently been published (21-23). In addition to high sensitivity, the ability to detect multiple mutations in a single experiment has also been demonstrated using picodroplet dPCR (20, 24, 25) . The multiplex procedure has been adapted to the analysis of DNA integrity within FFPE lung samples (25) and to the quantitative detection of the seven common mutations of KRAS (in codon 12 and 13) in plasma samples from patients with mCRC (26) . In this report, we have extended this multiplex dPCR technology to investigate the incidence of low-frequency KRAS mutations in patients with mCRC and the consequence of these mutations on the response to anti-EGFR therapy.
Research. 
Methods

Patients
Two cohorts of patients were pooled: one from an already published retrospective series, (8) and one from a prospective series, "CETRAS study," approved by the Ile-de-France ethical committee number 2 (ID-RCB 2007-AO124-49; AFSSAPS A70310-31). We selected all patients with KRAS, NRAS and BRAF wild-type tumors (n=136) for whom we have collected enough tissues to perform highly-sensitive picodroplet-dPCR and targeted next generation sequencing. We added to this selection of triple-negative patients, 41 patients with KRAS-mutated tumors selected from the retrospective series for whom, we had sufficient tumor material. Table 1 summarizes the clinical and pathological characteristics of the patients.
All patients were refractory to FOLFOX and/or FOLFIRI regimen and were treated with anti-EGFR antibodies with or without chemotherapy. The different regimens are described in Table   1 . The mean age was 62 years ± 11 and the gender ratio (M:F) was 1.33. The outcome measures were based on response evaluation criteria in solid tumor (RECIST), progression free survival (PFS), and overall survival (OS).
Tumors were collected at time of surgery. For the 177 patients, 206 tissues samples were available either as frozen samples (121), or formalin-fixed paraffin-embedded (FFPE) tissues (85).
Tumor cell content was assessed by Hematoxylin-Eosin-Safran staining. For paraffin-embedded tissues, manual selection of tumor rich area was performed on HES-stained slides, followed by manual dissection of serial unstained slides under x10 magnification. For frozen tissue, a HES staining procedure was also perform on different fragments and that containing the highest fraction of tumor cells was retained for DNA extraction. Among the tumor samples, 87% had a tumor cell content of 50% or more and the rest of the tumor samples contained between 20-40% of tumor cells. KRAS and BRAF mutation status were assessed by allelic discrimination using Taqman® qPCR probes as previously described (3, 8) and NRAS status was assessed by Sanger sequencing. determined as KRAS wild-type by qPCR. We tested 136 tumors to take into account some potential technical issues.
The Kruskal-Wallis test was used to calculate the P-value for association between the fraction of tumor KRAS-mutated allele and cetuximab response. PFS was calculated as the period from the first day of cetuximab treatment to the date of the tumor progression, to the date of death from any cause, or to the date of the last follow-up, at which point data were censored. OS was calculated as the period from the first day of cetuximab treatment until death from any cause or until the date for the last follow-up, at which point data were censored. A Cox model was used to estimate the effect of the fraction of KRAS-mutated DNA on survival. Both PFS and OS were estimated using the Kaplan-Meier method and compared using the log-rank test. A Cox model was used to estimate the effect of the fraction of KRAS-mutated allele(s) on survival. A receiver operating characteristics (ROC) analysis was performed in order to estimate a potential clinically relevant threshold for KRAS mutated allele fraction. Analysis was carried out using STATA (STATA corp, College Station, TX). The level of significance was set up at P=0.05.
Probes and primers design
The seven common KRAS mutations on codons 12 and 13 were assessed as previously described (3, 25, 26) . BRAF primers and probes were described elsewhere (22). The BRAF c.1799T>A (p.V600E) mutation detection was assessed by allelic discrimination using Taqman® probes following the same protocol as for the KRAS mutations. Primers and probes were procured through ABI. Taqman® Probes targeting wild-type sequence are conjugated to VIC TM (from ABI,  ex 528 nm /  em 554 nm), and probes targeting mutant sequences are labeled with 6-carboxyfluorescein (6-FAM,  ex 494 nm /  em 522 nm).
DNA controls
Genomic DNA was extracted from commercial cell lines purchased from American Type Culture Collection (ATCC CCL-231, ATCC CRL-5807, ATCC CCL-255, ATCC CCL-227, ATCC CRL-5877, ATCC HTB-53, and ATCC CCL-229). The heterozygous cell line bearing the c.34G>C (p.G12R) KRAS mutation was described previously (25). Genomic DNA was extracted using a QIAamp DNA mini Kit (Qiagen) and fragmented to an average size of 3000 bp using the S2 Focused Ultrasonicator (Covaris). DNA concentration was determined using a Nanodrop ND-1000 spectrophotometer. 
DNA preparation
When using genomic DNA extracted from tumor cell-lines, fragmentation of template DNA is necessary to decrease viscosity of the solution and allow rapid and stable droplet formation. This step was not required for DNA extracted from FFPE samples. However, for DNA extracted from frozen samples it was necessary to use a heat fragmentation step to ensure proper shearing of the genomic DNA. Briefly, frozen DNA was submitted to a 10 min 95°C denaturation step followed by a 15 min incubation at room temperature prior to analysis.
KRAS and BRAF mutation detection
The duplex assay is based on the parallel amplification of wild-type and specific mutant sequences. In a pre-PCR environment, 12. Assays for the detection of the seven mutations of KRAS located within codon 12 and 13
were assembled into two multiplex panels (a 4-and 5-plex dPCR assay) by mixing mutationspecific VIC and/or 6-FAM Taqman® probes with a single wild-type (VIC) probe and a single pair of PCR primers in each panel. Complete description of the droplet-based procedures, including assay linearity and dynamic range, used in this study are described elsewhere (26) .
All samples were assessed for the presence of the most frequent mutations of KRAS using the multiplex assay (26) . The BRAF c.1799T>A (p.V600E) mutation was screened using a duplex assay (26) .
Data analysis
Sensitivity of droplet-based PCR procedures is limited only by the number of molecules that can be amplified. As described earlier (26), the limit of detection of our assay is based on the limit of blank (LOB), and LOB is defined by the frequency of positive droplets measured in negative controls or controls with no DNA present. Based on these controls, the number of false positive droplet events (i.e., LOB) for each of the seven KRAS assays is: 2 for c.34G>C (P.G12R); 2 for c.35G>A (P.G12D); 1 for c.34G>T (P.G12C); 8 for c.35G>C (P.G12A); 2 for c.34G>A (P.G12S);
Research. assay. The sample analysis was performed following the procedure described earlier for the same assays (26) . The samples presenting low fraction of mutated allele(s) or ambiguous results (ie. presenting droplet cluster with very low amounts of droplets close to LOB or non clustered population of droplets) were submitted to the appropriate duplex assay(s) to confirm the presence of the mutation(s). Only samples appearing ositive in both experiments were classified as positives.
The others were classified as negatives.
Tumor DNA samples generally present a relatively small fraction of amplifiable DNA in particular in FFPE tumor samples (25) and therefore the measurement of amplifiable DNA molecules is an important metric. Among the frozen samples, the amplifiable DNA in the KRAS dPCR experiments ranged from 2,588 to 139,215 haploid genomes (mean = 37,329; median= 34,889). Among the FFPE samples, the amplifiable DNA ranged from 342 to 49,096 (mean = 8,076; median= 3,059).
Sequence enrichment and sequencing
DNA sample extracted from frozen tissues with less than 16µL total volume was normalized to a volume of 16µL with the addition of 10mM Tris pH 8.0 (Sigma). Each 16µL fresh frozen DNA sample was fragmented by heating to 95°C for 10 minutes in an Mastercycler pro S (Eppendorf).
DNA extracted from paraffin embedded tissues was not submitted to such treatment since they are already fragmented by the formalin fixation.
Primary PCR Reactions
All fresh frozen samples had sufficient material to input 100 ng of DNA per reaction (measurement of DNA based on the number of amplifiable genomes of each sample as previously determined by dPCR). When possible, 100 ng of FFPE was included in each PCR reaction. Each assay mix Each 50µL reaction was dropletized on the RainDrop Digital PCR Source using standard procedures. The amplification was carried out in a Mastercycler pro S (Eppendorf) as follows: 2 min at 94°C, 55 cycles of (30 s at 94°C, 30 s at 54°C and 60 s at 68°C) and finally 10 min at 68°C.
After thermal cycling, 70µL of droplet destabilizer (Raindance Technologies) was added to each sample, briefly vortexed and spun in a microcentrifuge. After addition of 2µL of 3M NaOAc pH 5.2, the aqueous portion of each sample was purified using the Qiacube Automated Sample Prep System in conjunction with the standard MinElute PCR Purification Kit/Protocol and an elution volume of 15µL. Each sample was quantified by running 1 µL of the purified sample on the Agilent 2100 Bioanalyzer using the DNA 12000 kit standard protocol. Only the concentration of the target peak (~200bp) was used to determine the input volume for secondary PCR.
Secondary PCR and Cleanup
When possible, 10 ng of primary PCR product was included in each secondary PCR reaction; however, for samples where there was little or no amplification in the primary PCR reaction as detected on the Agilent Bioanalyzer, a total of 13 µL of the primary PCR reaction was added. The 
Sequencing
Using 10mM Tris-HCl pH 8.0, 1µL of each sample was diluted to a concentration of 2nM. In contrast to quantifying the primary PCR products for secondary PCR, all material produced by the secondary PCR amplification -not just the ~300bp target peak -was considered when diluting the sample for sequencing. An equal portion of each diluted sample was combined to produce a 2nM pool containing 48 total samples each with a different six base index.
Sequencing was performed on an Illumina MiSeq instrument with the 500 cycle kit (part #: MS-102-2003) using the standard protocol for 250 base paired end reads with the exception that custom sequencing primers, as described below were substituted for the standard Illumina sequencing primers.
The sequences of the custom sequencing primers were as follows:
Read 1 Custom Sequencing Primer (5' -3') Loaded in MiSeq Cartridge Well #18
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTG
Read 2 Sequencing Primer (5' -3') Loaded in MiSeq Cartridge Well #20
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGAC
The custom sequencing primers are identical to the standard Illumina sequencing primers except for the addition of 3 bases on the 3' end (shown in red) which dictate the end of the amplicon to which the secondary PCR primers will hybridize and extend.
Results
Of the 177 patients included in this study, 61 were responders, in one case, the response was not evaluable and the others were not responders ( Figure 1 ). Tumor DNA extracted from this series was analyzed with picodroplet-dPCR. Additionally, part of KRAS exon 2 and BRAF exon 15 from 167 of these patients were analyzed with deep next-generation sequencing (Table 2 and   Supplementary Table 1 ).
All tumors were analyzed by multiplex dPCR targeting the seven mutations of the KRAS oncogene (see supplementary information). This multiplex assay has been described elsewhere including assay linearity and dynamic range (26) . First (Fig. 2, left 
status of the samples (positivity threshold was set up at 1% for NGS results) was in agreement with dPCR results for 97% of the samples (162/167, see supplementary Table 1 ). We observed a correlation with the observed fraction of mutant alleles with the two procedures (r square of 0.8 for all detected alleles).
We observed an inverse correlation between the proportion of mutated DNA and the frequency of anti-EGFR response (Figure 3, P<0.001) . The mean percentage of mutated DNA was 0.45% and 12.5% for responders and non-responders, respectively. Only two patients were classified as responders with a KRAS mutant allele fraction greater than 10%. In a first analysis, we In a second analysis, we categorized patients into quartiles of KRAS mutant allele fraction (cut off of 0.57%, 21.3% and 40.3%). We observed an inverse association between the quartile and the response rate. Among the 63 patients with at least one positive test (i.e., qPCR or dPCR), the response rate was evaluable for 62. Among them, the 12 patients that were responders belong to the first two quartiles, whereas 31 of the 50 non-responders belong to the third and fourth quartiles.
This difference is statistically significant (P<0.001). Furthermore, a Kaplan-Meier survival curve showed an inverse correlation between PFS or OS and the categorization of samples into the different quartiles (P<0.001). Furthermore, patients in the lowest quartile have comparable PFS and OS to those patients without detectable mutations (Figure 4, A and B) .
We tried to determine a potential clinically-relevant threshold for the ratio of mutant allele.
We estimated the diagnostic value (response rate) of the fraction of KRAS-mutated alleles by performing a receiver operating characteristics (ROC) curve analysis. The area under the curve (AUC) was 0.89. The optimal value of KRAS-mutated alleles was 1.5% with 87% of correctly classified patients for response status (ie. responders versus non responders). We therefore choose the value of 1% to dichotomize the patients with no mutations detected by qPCR (n=136). There is evidence that patients with a tumor mutated with more than 1% of a mutant allele have a significantly worse prognosis than those negative by both qPCR and dPCR or those with less than 1% mutant allele fraction. When comparing patients with non-mutated tumors or with tumors presenting 1% or less of a mutated allele to patients with tumor with more than 1% of mutated allele, the hazard ratios were 3. Figure 4, C and D) . Furthermore, considering that 5 patients had a fraction KRAS-mutated allele between 1 to 10%, the relevant clinical cut-off value can not be precisely define and reasonably between 1 and 10% therefore we can estimate that usual standard procedures of KRAS mutant detection missed, at the maximum, 3.6% of clinically relevant KRAS mutation (CI95%[1.2-8.3%]) and therefore this percentage accounts for unexplained resistance in "KRAS wild-type patients".
Discussion
In this work, the high sensitivity and precision of picodroplet-dPCR enabled detection and quantification of rare KRAS and BRAF-mutated alleles in tumor samples with the aim of understanding the importance of sub-clones for patient treatment management. Indeed even if KRAS mutations have been described as the major predictive factor for resistance to anti-EGFR responses, a large proportion of patients (40-60%) with a tumor classified as non mutated do not respond to such therapies (7).
Many research studies have been conducted to try to understand and overcome these treatment failures, including strategies aimed at finding mutations in other genes of the EGFRdependent signaling pathways (8-10). However, except for extended RAS mutations (10), none of the candidate genes get through clinical validation. Another approach has been to focus on developing and applying new, highly sensitive procedures to detect low frequency KRAS alleles and make correlations to clinical data to understand the importance of the rare mutations.
Various studies have highlighted that sensitive molecular analysis methods would allow clinicians to identify all patients that will not benefit from Cetuximab (1, (28) (29) (30) . For example, in the largest series published (1, 29) , the authors used sensitive methods of detection (pyrosequencing or MALDI-TOF MS, mutant enriched-PCR and engineered mutant-enriched PCR) to demonstrate that the patients with mutations identified by methods more sensitive than direct sequencing are more likely to have a lower response rate or worse PFS.
These series compared different methods of KRAS detection to Sanger sequencing, which is known to present low sensitivity for the detection of specific mutation. Furthermore the question raised by these studies is the lower limit of detection of mutation, which has a clinical relevance to give some clinical guidance, underlining the need of truly quantitative methods leading to robust results and to alleviate possible experimental bias. Droplet-based dPCR, which employs thousands to millions of aqueous droplets to compartmentalize a DNA sample, has emerged as a promising strategy for the analysis of clinical samples (26, (31) (32) (33) . Digital PCR is both precise and sensitive due to discrete counting of the mutant and wild-type alleles present in a sample (34, 35) . The sensitivity is only limited by the number of molecules that can be analyzed and the false positive rate of the mutation detection assay. Another advantage of microfluidic droplet-based procedures is the possibility to quantify the amount of amplifiable DNA in tested samples. This quantification corresponds to an internal positive control of the assay and allows definition of the limit of detection attainable for this particular sample (25).
In this study, we used picodroplet digital procedures (see (19) for a review) to highlight low frequency KRAS or BRAF mutated clones as previously described (20, 22, 26) . In addition to 41 KRAS-mutated tumors that were included as positive controls, 136 tumor samples that were characterized by qPCR as negative for KRAS, BRAF, and NRAS mutations were analyzed by picodroplet-dPCR. As expected, the procedure enabled detection of all tumors with a KRAS mutation identified by conventional procedures (n=41). Among the 136 remaining tumors, 22
were positive for a KRAS mutation (16%) and two were positive for the BRAF c.1799T>A Moreover, this study revealed three patients that presented multiple KRAS mutations in their blood. The occurrence of multiple sub-clones after treatment by anti-EGFR therapy is also consistent with the number observed in our study (6 patients with multiple sub-clones in their tumors). The slightly lower percentage of mutated patients observed in our study are expected since circulating tumor blood DNA is a better sampling of the tumor heterogeneity than that from a small part of the primary tumor (36).
As described in previous studies, nearly all patients with KRAS-mutated tumor samples that were identified by bulk procedures were non-responders (40/41, 97.5%). However, among the newly identified KRAS-mutated tumors, half of them (11/22) belong to responder patients.
Furthermore, we observed an inverse correlation between the proportion of mutated DNA and the frequency of anti-EGFR response (P<0.001). If we consider all patients positive for a mutation, 75% of the patients in the lowest quartile were responders, 25% of the second quartile were responders, and none of the patients in the upper two quartiles were responders. Using receiver operating characteristic analysis, the cut-point allowing the highest percentage of correctly classified patients is 1.5%. If we consider a cut-off value of 1%, only 2 patients (out genetics in the blood. Nature reviews Clinical oncology. 2013;10:472-84.
37.
Bellon E, Ligtenberg MJ, Tejpar S, Cox K, de Hertogh G, 
